UBS Group AG

UBS Group AG (10% owner) bought 3,715 shares of NDRA at $0.55 on 2024-08-27; stock down -99.7% from 52-week high to $14.70.

UBS Group AG, a major 10% shareholder in ENDRA Life Sciences, purchased 3,715 shares at $0.55 on 2024-08-27, adding modestly to its 146,012-share position (+2.6% vs pre-transaction holdings). The stock has since cratered -99.7% from its 52-week high and is down -90.2% over the past 30 days and -96.9% over 90 days. ENDRA posted $0.00 revenue in its latest quarter and $-2,229,153.00 net income for the period, reflecting a deeply unprofitable operating profile with a $1.1B market cap. While UBS's cross-ticker track record shows strong historical returns on prior buys (avg 30d return +2593.6%), this purchase occurred at a price that has proven to be the start of a severe drawdown, not an opportune accumulation point.

UBS (10% owner) sold 1,265 shares (1.3K) for $5.5K while buying 108 shares for $488.82; net reduction of 1,157 shares (-4.4%)

UBS Group AG, holding 25.0K shares post-transaction, executed 18 separate sales totaling 1,265 shares for $5,470.96 against 5 purchases totaling 108 shares for $488.82 on July 5–8, 2024. The net effect was a 4.4% reduction in holdings. This substantial liquidation by a significant shareholder occurs against a backdrop of severe operational challenges: the company reported quarterly revenue of $1,033,548.00 with a net loss of $-26,048,044.00, negative full-year profitability, and annual revenue contraction of -28.3%. The stock's 52-week performance shows a -100.0% decline from its high, and the 30-day and 90-day price changes stand at -54.9% and -86.8% respectively, indicating sustained deterioration. The timing and magnitude of this net sell position a major stakeholder's shift away from the company during a period of acute financial distress.